Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Y RNAs are a conserved family of small non-coding RNAs essential for key cellular processes. In humans, four main types (hY1, hY3, hY4, hY5) are expressed, ranging from 83 to 112 nucleotides in length. They possess a characteristic stem-loop structure and predominantly bind to the Ro60 and La proteins, forming ribonucleoprotein complexes involved in RNA quality control and stability. Distinct domains within Y RNA mediate chromatin association and the initiation of chromosomal DNA replication, a function separate from their interactions with Ro60. Y RNAs also give rise to stable small fragments (ysRNAs), which are increasingly studied as disease biomarkers. Overexpression of Y RNAs or their fragments has been linked to tumorigenesis, autoimmunity (especially systemic lupus erythematosus, by being recognized by patient autoantibodies), infections, and heart disease. Despite their crucial biological roles and disease associations, Y RNAs are not classical therapeutic drug targets such as receptors, channels, or enzymes, and direct pharmacological interventions are not established[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Y RNA.